Overview of United States Post-Market Obligations for Medical Devices

1. Key takeaways

The post-market obligations for medical devices in the United States form five parallel lines: the annual registration update (October 1 through December 31), listing maintenance (including inactivation and reinstatement), MDR reporting (21 CFR 803), UDI and GUDID (21 CFR 830), and corrections and removals reporting (21 CFR 806). Each of the five lines carries its own deadlines and legal basis, and a gap in any one of them creates a compliance hole. The lines differ not only in deadline but also in the kind of duty they impose, so they cannot be assessed with one uniform test.

Because the lines run in parallel rather than in sequence, no single process can discharge all of them, and the management system must be built so that each line has its own trigger, its own clock, and its own records. A brief that covers all five in one page is a useful training tool, but it is not a substitute for the underlying procedures, and auditors will expect to see the per-line detail behind the summary.

2. Legal basis

The five lines rest on the following provisions, cited with their Federal Register sources where applicable, in force as of the verification date noted at the end of this page.

3. Expert insights

Insight one: the deadline logic differs across the five lines.

Annual registration and listing operate on a calendar window (October 1 to December 31); MDR for manufacturers is 30 calendar days (5 working days for events requiring remedial action); UDI and GUDID involve continuous data maintenance; corrections and removals run on 10 working days. A unified reminder mechanism must therefore be configured separately for each line, because a single alarm logic cannot serve a calendar window, an event clock, and a continuous duty at the same time. The practical estimate is that each line needs its own reminder type: a seasonal task, a countdown, and an embedded process step. When these are configured once and reviewed annually, the five lines stop competing for attention and start reinforcing one another, since several of them draw on the same device and facility data.

Insight two: receiving a 510(k) does not end the obligations; it switches them onto a new track.

Before market entry the mode is submission and review; after market entry the mode is reporting and maintenance. When a company receives its substantial equivalence letter, the processes for all five lines should already be live, rather than being built after an event occurs. Waiting for the first adverse event or the first correction to stand up the reporting machinery guarantees that the first real deadline is met under improvised conditions, which is precisely when the risk of a missed filing is highest. Readiness at the moment of clearance is therefore a testable state: the five lines should each be able to show a named owner, a written procedure, and a record trail on the day the substantial equivalence letter arrives.

Insight three: the five lines converge at customs clearance.

Expired registration or expired listing leads to detention under Import Alert 99-34. The execution quality of post-market obligations is therefore reflected directly in how smoothly goods clear import. A company may hold a valid 510(k) and still see its shipments detained if the annual update window was missed or a listing was inactivated, which makes the calendar-window lines just as commercially sensitive as the event-driven reporting lines. Importers feel this convergence first, because their goods bear the consequences of upstream lapses they may not directly control.

Insight four: together the five lines form the evidentiary surface for FDA inspections.

Under 21 CFR Part 820 (the QMSR, effective 2026-02-02) and FDA Import Alert 99-34, FDA inspections and clearance verification reach into the records of all five lines. Missing records create quality system deficiencies and clearance risk at the same time, pending verification against the current FDA guidance. The same filing that protects the shipment at the border is the document the investigator asks for during the inspection, which argues for maintaining the records once, properly, rather than reconstructing them for each audience. In our practical estimate, a company that can retrieve all five record sets on request is also the company whose clearance files pass without challenge.

4. Practical recommendations

• Manage the obligations with a five-line table: for each line list the governing provision, the deadline, the responsible person, and the record location.
• Bring all five-line processes live before receiving the 510(k) substantial equivalence letter.
• Set the calendar-window items (annual registration and listing) as fixed work items starting October 1 each year, with completion verified before December 31.
• For event-driven lines (MDR, Part 806), set up countdown processes and defined trigger assessment criteria.
• Tie the continuous maintenance line (UDI and GUDID) to the product change process, so every design or labeling change updates the data as a by-product of the change control.

5. Verification checklist

• □ A five-line table has been established (provision, deadline, responsible person, record location)
• □ The October 1 to December 31 work item for annual registration and listing has been set
• □ The 30 calendar day and 5 working day MDR processes are live
• □ The 10 working day corrections-and-removals process is live
• □ UDI and GUDID maintenance has been tied to the product change process
• □ Records for all five lines can be retrieved during an inspection

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com